Biora Posts Positive Results on Its Xeljanz Delivery Method

Biora Therapeutics said that its drug delivery system of the liquid formulation of tofacitinib, the active ingredient in Pfizer’s Xeljanz, showed promising results in a study.

The results showed that all capsules were safely ingested and exited the body naturally, with no serious adverse events reported.

No actual drugs were administered in the study, but a separate study examining the drug delivery method’s performance in active ulcerative colitis patients is under way.

Xeljanz, a Janus kinase inhibitor, is FDA-approved for several indications, including for patients with moderate-to-severe active ulcerative colitis.